Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition

Respir Investig. 2024 May;62(3):402-418. doi: 10.1016/j.resinv.2024.02.014. Epub 2024 Mar 14.

Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with a poor prognosis and an unknown cause that generally progresses to pulmonary fibrosis and leads to irreversible tissue alteration. The "Guidelines for the treatment of idiopathic pulmonary fibrosis 2017," specializing in the treatment of IPF for the first time in Japan and presenting evidence-based standard treatment methods suited to the state of affairs in Japan, was published in 2017, in line with the 2014 version of "Formulation procedure for Minds Clinical Practice Guidelines." Because new evidence had accumulated, we formulated the "Guidelines for the treatment of Idiopathic Pulmonary Fibrosis 2023 (revised 2nd edition)." While keeping the revision consistent with the ATS/ERS/JRS/ALAT IPF treatment guidelines, new clinical questions (CQs) on pulmonary hypertension were added to the chronic stage, in addition to acute exacerbation and comorbid lung cancer, which greatly affect the prognosis but are not described in the ATS/ERS/JRS/ALAT IPF guidelines. Regarding the advanced stages, we additionally created expert consensus-based advice for palliative care and lung transplantation. The number of CQs increased from 17 in the first edition to 24. It is important that these guidelines be used not only by respiratory specialists but also by general practitioners, patients, and their families; therefore, we plan to revise them appropriately in line with ever-advancing medical progress.

Keywords: Japanese Respiratory Society; acute exacerbation; complicated lung cancer; guideline for the treatment; idiopathic pulmonary fibrosis.

MeSH terms

  • Humans
  • Idiopathic Pulmonary Fibrosis* / therapy
  • Japan / epidemiology
  • Lung Diseases, Interstitial*
  • Lung Neoplasms*
  • Prognosis